Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: ghmm who wrote (3954)	10/17/2015 10:32:14 PM
From: jaybe	1 Recommendation Recommended By ghmm Read Replies (1) \| Respond to of 4474

I think this could be huge for pona. I've been tracking this trial for a year or so and I think they used 150mg, half of the approved frontline CML dose. Since we know nilo crosses the BBB at 5-6% of plasma concentrations and pona crosses the BBB at over 200% of plasma concentrations (see pona patent for PD/AD), it could be that very low doses of pona, 5-10mg, would be effective. First order of business is to demonstrate a 15mg dose in CML has very few side effects and no SAE's. This data will come with the OPTIC trial and could be available at ASH 2016. Ariad would definitely partner a non-oncology indication, but with 3M patients in the developed world any potential royalty would still be Ariad's biggest revenue generator by far.